無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

日本のジェネリック医薬品市場の分析

Japan Generics Market Analysis

発行 RNCOS E-Services Pvt. Ltd. 商品コード 231240
出版日 ページ情報 英文 55 Pages
即納可能
価格
こちらの商品の販売は終了いたしました。
Back to Top
日本のジェネリック医薬品市場の分析 Japan Generics Market Analysis
出版日: 2012年02月01日 ページ情報: 英文 55 Pages

当商品の販売は、2018年07月02日を持ちまして終了しました。

概要

日本の医薬品市場は世界第2位の規模ですが、一般的認識の問題からジェネリック医薬品のシェアは低い状態が続いてきました。しかし医療費支出の増大などを受けて、政府はジェネリック医薬品の普及に積極的に取り組んでいます。先発医薬品や有効成分の特許失効もまた、将来の大きな市場促進要因となるものと思われます。日本のジェネリック医薬品市場は2010年に約90億ドルの規模に達し、そして今後は医薬品市場全体を上回る勢いで拡大するものと推測されます。

当レポートでは、日本におけるジェネリック医薬品(後発医薬品)市場について分析し、近年の市場の動向や全般的な市場構造、政府の規制と支援策、今後の市場機会、主要企業のプロファイルなどの情報を盛り込んで、概略以下の構成でお届けします。

第1章 アナリストの見解

第2章 分析手法

第3章 近年の市場の動き

  • 保険薬局とDPC(診断群分類別包括評価制度)導入病院:ジェネリック医薬品への大きな貢献
  • 日本市場:大手医薬品企業にとっての、ジェネリック医薬品の新たな中核的市場
  • ジェネリック癌治療薬:急激な成長の見通し

第4章 人口構成概況

第5章 日本の医薬品市場の見通し(2014年まで)

第6章 日本のジェネリック医薬品市場の概況

  • 医療費支出
    • 疾患別・年齢層別の支出額
  • ジェネリック医薬品の普及率
  • ジェネリック医薬品市場の見通し(2014年まで)
  • ジェネリック処方薬とジェネリックOTC医薬品
  • 流通システム
    • 医療機関別
    • 流通経路別
  • 近年のジェネリック医薬品の発売状況

第7章 消費者行動の分析

  • 患者側の意見
  • 医師・薬剤師側の意見

第8章 規制環境

  • 厚生労働省(MHLW)の役割
  • ジェネリック医薬品の認可および販売許可に際しての主な要件
  • 特許制度

第9章 政府の主な促進策

第10章 市場機会の評価

  • 特許失効
  • 治療処置

第11章 主要企業

  • 日医工
  • 沢井製薬
  • 大洋薬品工業
  • 東和薬品
  • Meiji Seika ファルマ
  • 日本ケミファ

図表一覧

目次

Abstract

Japan is the world's second largest pharmaceutical markets in the world, but due to public perception, the share of generic drugs has remained low in it. However, worried over rising healthcare expenses and high mortality rates, the government has now been playing a vital role in promoting generics. The patent expiry of branded drugs and active ingredients will also act as a strong growth driver for the market in future. According to the findings of our latest report, the generics market in Japan stood at around US$ 9 Billion in 2010. It estimates that the growth in generic drugs will outshine the expansion in overall pharmaceutical market.

According to "Japan Generics Market Analysis", Japan is expected to be the next generic hub, and cancer related generics exhibit vast potential. The report finds out how vital is the role of National Health Insurance (NHI) pharmacies and Diagnosis Procedure Combination (DPC) hospitals in the industry development. It was observed that the DPC hospitals, in particular, have been growing at a robust rate, promoting generics penetration. We also found that ethical generics hold the majority share in the generic drugs market.

A detailed demographic analysis was carried out in the research that revealed that the population aged 65 years and above accounts for maximum healthcare-related expenditures in Japan, and hence becomes the target population for generics promotion. Further, a meticulous disease and age-wise segmentation has provided the holistic understanding of the healthcare-related demand parameters prevailing in the country.

The government in Japan has taken several initiatives to ensure growth and promotion of generics industry in the country. Recently, special premium-based incentives have been given to pharmacists on generic promotion. In near future, the government plans to bring in more reforms in medical care system. Our research talks about such revisions and reforms briefly to present a balanced outlook of the industry to clients. Analysis of current trends, profiles of key players in the Japanese generic market, and recent developments in the industry have also been included in the comprehensive study.

Table of Contents

1. Analyst View

2. Research Methodology

3. Recent Market Trends

  • 3.1 NHI Pharmacies and DPC Hospitals to Contribute Majorly in Generics
  • 3.2 Japan: Next Generic Hub for Pharma Majors
  • 3.3 Cancer Generics Projected for Exorbitant Growth

4. Demographics Profile

5. The Japanese Pharmaceutical Market Outlook to 2014

6. The Japanese Generic Drugs Market Overview

  • 6.1 Healthcare Expenditure
  • 6.1.1 Expenditure by Disease and Age Group
  • 6.2 Generics Penetration
  • 6.3 Generics Market Outlook to 2014
  • 6.4 Ethical vs OTC Generics
  • 6.5 Distribution System
  • 6.5.1 By Medical Institution
  • 6.5.2 By Distribution Channel
  • 6.6 Recent Generic Launches

7. Consumer Behavior Analysis

  • 7.1 Patients View
  • 7.2 Physicians and Pharmacist View

8. Regulatory Environment

  • 8.1 Role of MHLW
  • 8.2 Key Requirements for Generics Approval and Marketing Authorization
  • 8.3 Patent System

9. Key Government Initiatives

10. Opportunity Assessment

  • 10.1 By Patent Expiration
  • 10.2 By Therapeutic Treatment

11. Key Players

  • 11.1 Nichi-Iko
  • 11.2 Sawai Pharmaceuticals
  • 11.3 Taiyo Pharmaceutical
  • 11.4 Towa
  • 11.5 Meiji Seika
  • 11.6 Nippon Chemipher

List of Figures:

  • Figure 3-1: Cancer Mortality Rate (per 100,000 Population), 2000 & 2010
  • Figure 5-1: Pharmaceutical Market (Billion US$), 2010-2014
  • Figure 5-2: Share of Generics in Pharmaceutical Market (2011)
  • Figure 5-3: Pharmaceutical Sales by Facility (%), 2009
  • Figure 6-1: Healthcare Expenditure (Billion US$), 2010 & 2015
  • Figure 6-2: Percentage Distribution of Healthcare Expenditure by Diseases for Population Aged below 65 (2008)
  • Figure 6-3: Percentage Distribution of Healthcare Expenditure by Diseases for Population Aged 65 and Above (2008)
  • Figure 6-4: Share of Generic Drugs in Pharmaceuticals Market w.r.t Developed Countries (2009)
  • Figure 6-5: Generic Drugs Market (Billion US$), 2010-2014
  • Figure 6-6: Market Share of Generic Drugs Manufacturers (2010)
  • Figure 6-7: Generic Drugs Market by Segment (%), 2009
  • Figure 6-8: Generic Drugs Market by Medical Institution (%), 2008 & 2009
  • Figure 6-9: Number of DPC Hospitals (FY 2007 to FY 2010)
  • Figure 6-10: Generic Drugs Market by Distribution Channel (%), 2008 & 2009
  • Figure 11-1: Sawai Pharmaceutical - Sales by Therapeutic Category (%), FY 2010
  • Figure 11-2: Towa Pharmaceutical - Sales by Therapeutic Category (%), Mar 2011

List of Tables:

  • Table 3-1: Recent Industry Activities in Cancer Generics
  • Table 4-1: Demographic Characteristics (2010 & 2015)
  • Table 6-1: Recent Generic Drugs Launch of Key Players (2011)
  • Table 8-1: Application Fee for Manufacturing and Marketing of Generics (JPY)
  • Table 9-1: Key Measures for Generic Drugs Promotion
  • Table 10-1: Patent Expiry of Key Drugs in Japan (2012-2015)
Back to Top